Blockchain Registration Transaction Record

Kairos Pharma CEO to Present at LD Micro Invitational

Kairos Pharma CEO Dr. John Yu to present at LD Micro Invitational on May 18, 2026. Update on ENV-105 clinical trials for prostate and lung cancer. Learn about CD105 antibody targeting drug resistance.

This news matters because it provides investors and the medical community with a timely update on Kairos Pharma's clinical progress for ENV-105, a promising therapy targeting drug resistance in cancer. The presentation at a major investment conference signals potential partnership opportunities and could influence the company's stock performance. For patients, ENV-105 represents hope for more effective treatments against resistant cancers like prostate and lung cancer, addressing a critical unmet need in oncology.